Govorestat (at-007) receives orphan medicinal product designation from the ema for treatment of sord deficiency

New york, may 25, 2023 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that at-007 (govorestat) has been granted orphan medicinal product designation by the european medicines agency (ema) for treatment of sorbitol dehydrogenase (sord) deficiency. additionally, the company announced that new data has been published in the journal of clinical investigation on govorestat treatment in models of sord deficiency.
APLT Ratings Summary
APLT Quant Ranking